Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIREFLY-1 Phase 2 Tovorafenib in Pediatric RAF-Altered Tumors
2024-510691-20-00Phase 2Authorised
- Sponsor
- Day One Biopharmaceuticals
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of tovorafenib in glioma and Nonhematologic neoplasms (3 arms), sponsored by Day One Biopharmaceuticals. Planned start Jul 2024; status: authorised.
02
Drugs
tovorafenib
03
Conditions
gliomaNonhematologic neoplasms
Beyond the preview
Go deeper on 2024-510691-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510691-20-00.